Atika Capital Management’s Dianthus Therapeutics DNTH Stock Holding History
Bought
Maintained
Sold
Other funds holding DNTH
Atika Capital Management's DNTH Position: Q3 2026 in Review
Atika Capital Management reduced its Dianthus Therapeutics (DNTH) stake by 41% in Q3 2026, selling an estimated $7.06M and leaving 97,000 shares worth $8.54M. The position accounts for 0.69% of the portfolio, ranked #40.
Atika Capital Management first reported a position in DNTH in Q4 2025 and has held it in 4 quarters since. The position peaked at $16.1M in Q2 2026. 275 funds tracked by Wall St. Rank hold DNTH as of Q3 2026.
- Atika Capital Management held 97,000 shares of Dianthus Therapeutics worth $8.54M as of Q3 2026.
- Atika Capital Management sold 68,000 Dianthus Therapeutics shares in Q3 2026, an estimated $7.06M.
- Dianthus Therapeutics made up 0.69% of Atika Capital Management's portfolio in Q3 2026, its #40 holding.
- Atika Capital Management first reported a position in Dianthus Therapeutics in Q4 2025 and has held it in 4 quarters since.
- Atika Capital Management's Dianthus Therapeutics position peaked at $16.1M in Q2 2026.
- 275 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q3 2026.
Based on Atika Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.